UNIVEST FINANCIAL Corp Buys 5,671 Shares of Becton Dickinson and Co (NYSE:BDX)

UNIVEST FINANCIAL Corp raised its stake in Becton Dickinson and Co (NYSE:BDX) by 34.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 22,360 shares of the medical instruments supplier’s stock after purchasing an additional 5,671 shares during the quarter. Becton Dickinson and comprises approximately 1.6% of UNIVEST FINANCIAL Corp’s holdings, making the stock its 18th biggest position. UNIVEST FINANCIAL Corp’s holdings in Becton Dickinson and were worth $3,702,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Allworth Financial LP increased its holdings in Becton Dickinson and by 386.4% in the 3rd quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 85 shares during the last quarter. Northwest Investment Counselors LLC purchased a new position in shares of Becton Dickinson and during the 3rd quarter worth about $27,000. Liberty Wealth Management LLC boosted its stake in shares of Becton Dickinson and by 293.1% during the 3rd quarter. Liberty Wealth Management LLC now owns 114 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 85 shares during the period. CX Institutional purchased a new position in shares of Becton Dickinson and during the 3rd quarter worth about $31,000. Finally, North Star Investment Management Corp. purchased a new position in shares of Becton Dickinson and during the 3rd quarter worth about $45,000. Institutional investors own 84.46% of the company’s stock.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 33,365 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $271.28, for a total value of $9,051,257.20. Following the completion of the sale, the chief executive officer now directly owns 254,312 shares of the company’s stock, valued at approximately $68,989,759.36. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Vincent A. Forlenza sold 11,626 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $265.57, for a total transaction of $3,087,516.82. Following the completion of the sale, the chief executive officer now directly owns 225,393 shares of the company’s stock, valued at approximately $59,857,619.01. The disclosure for this sale can be found here. Over the last three months, insiders sold 91,231 shares of company stock valued at $24,787,690. 0.12% of the stock is owned by corporate insiders.

A number of equities analysts recently commented on BDX shares. Morgan Stanley lifted their price target on shares of Becton Dickinson and from $261.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 17th. Barclays cut shares of Becton Dickinson and from an “overweight” rating to an “equal weight” rating and set a $275.00 price target for the company. in a research note on Wednesday, January 8th. Stifel Nicolaus lifted their price target on shares of Becton Dickinson and from $275.00 to $295.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. JPMorgan Chase & Co. lifted their price target on shares of Becton Dickinson and from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. Finally, KeyCorp dropped their price target on shares of Becton Dickinson and from $262.00 to $256.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th. Six analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $277.70.

Becton Dickinson and stock traded down $0.24 during trading hours on Tuesday, hitting $275.96. The company had a trading volume of 1,441,453 shares, compared to its average volume of 1,344,217. The firm has a market cap of $74.23 billion, a P/E ratio of 23.63, a P/E/G ratio of 1.96 and a beta of 1.07. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.72 and a current ratio of 1.18. Becton Dickinson and Co has a 1 year low of $221.47 and a 1 year high of $277.45. The company has a 50-day moving average price of $267.04 and a two-hundred day moving average price of $255.81.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.30 by $0.01. The company had revenue of $4.58 billion during the quarter, compared to analysts’ expectations of $4.57 billion. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.52%. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.93 EPS. As a group, equities research analysts anticipate that Becton Dickinson and Co will post 12.57 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Tuesday, December 10th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 1.15%. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.77. The ex-dividend date was Monday, December 9th. Becton Dickinson and’s payout ratio is 27.05%.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: P/E Growth (PEG)

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.